{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T08:02:51Z","timestamp":1789718571170,"version":"4.0.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T00:00:00Z","timestamp":1736899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Hereditary predisposition to breast and ovarian cancer syndrome (HBOC) is a pathological condition with increased cancer risk, including breast (BC), ovarian cancer (OC), and others. HBOC pathogenesis is caused mainly by germline pathogenic variants (GPV) in\n                      <jats:italic>BRCA1<\/jats:italic>\n                      and\n                      <jats:italic>BRCA2<\/jats:italic>\n                      genes. However, other relevant genes are related to this syndrome diagnosis, prognosis, and treatment, including\n                      <jats:italic>TP53<\/jats:italic>\n                      ,\n                      <jats:italic>PALB2<\/jats:italic>\n                      ,\n                      <jats:italic>CHEK2<\/jats:italic>\n                      ,\n                      <jats:italic>ATM<\/jats:italic>\n                      , etc. This study aimed to identify the prevalence of non-\n                      <jats:italic>BRCA<\/jats:italic>\n                      genes in HBOC patients of Northeast Mexico.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This multicentric study included 1285 patients with HBOC diagnosis from four oncologic centers in northeast Mexico from 2016 to 2023. Genomic and clinical data were analyzed based on multi-gene panel results and electronic records of the medical geneticist consultation. For the data analysis of qualitative and quantitative variants, JASP statistical software (version 0.18.1) was used, taking p\u2009&lt;\u20090.05 as a significant result.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      We found that 32.7% of the patients had at least one GPV in non-\n                      <jats:italic>BRCA<\/jats:italic>\n                      genes. The five most frequent non-\n                      <jats:italic>BRCA<\/jats:italic>\n                      genes were\n                      <jats:italic>CHEK2<\/jats:italic>\n                      ,\n                      <jats:italic>PALB2<\/jats:italic>\n                      ,\n                      <jats:italic>MUTYH<\/jats:italic>\n                      ,\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      , and\n                      <jats:italic>ATM<\/jats:italic>\n                      . Among the group of non-\n                      <jats:italic>BRCA<\/jats:italic>\n                      genes, six are involved in the homologous repair pathway (HR), and three are related to DNA damage repair (DDR) pathways. In analyzing GPVs in molecular pathways, both have similar frequencies with no statistical difference for BC.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      Multi-gene testing implementation improves the detection of often overlooked genes related to HBOC pathogenesis and treatment. Non-\n                      <jats:italic>BRCA<\/jats:italic>\n                      GPVs in Northern Mexico correspond to one-third of the HBOC cases, including HR and DDR pathways genes that would be misdiagnosed if not tested. HR patient carriers are potential targets of iPARP therapies. The optimal approach to cancer treatment for non-\n                      <jats:italic>BRCA<\/jats:italic>\n                      mutation carriers warrants further investigation to develop newer therapies.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13058-024-01957-9","type":"journal-article","created":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T10:37:37Z","timestamp":1736937457000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Los olvidados: Non-BRCA variants associated with Hereditary breast cancer in Mexican population"],"prefix":"10.1186","volume":"27","author":[{"given":"Dione","family":"Aguilar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Lourdes","family":"Garza-Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolina Elizabeth","family":"Mu\u00f1iz-Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Alcorta","family":"Nu\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia Mayte","family":"Villarreal-Garza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Vidal-Guti\u00e9rrez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana Cristina","family":"P\u00e9rez-Ibave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos Horacio","family":"Burciaga-Flores","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,15]]},"reference":[{"issue":"4","key":"1957_CR1","doi-asserted-by":"publisher","first-page":"255","DOI":"10.7326\/M13-1684","volume":"160","author":"HD Nelson","year":"2014","unstructured":"Nelson HD, Pappas M, Zakher B, Mitchell JP, Okinaka-Hu L, Fu R. Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer in women: a systematic review to update the U.S. Preventive Services Task Force recommendation. Ann Intern Med. 2014;160(4):255\u201366.","journal-title":"Ann Intern Med"},{"key":"1957_CR2","doi-asserted-by":"publisher","first-page":"102356","DOI":"10.1016\/j.pmedr.2023.102356","volume":"35","author":"JL Lasta","year":"2023","unstructured":"Lasta JL, Groto AD, Brandalize APC. Assessment of medical knowledge toward genetic testing for individuals with hereditary breast and ovarian cancer syndrome in Brazil. Prev Med Rep. 2023;35:102356.","journal-title":"Prev Med Rep"},{"issue":"5","key":"1957_CR3","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1086\/375033","volume":"72","author":"A Antoniou","year":"2003","unstructured":"Antoniou A, Pharoah PD, Narod S, Risch HA, Eyfjord JE, Hopper JL, Loman N, Olsson H, Johannsson O, Borg A, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117\u201330.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1957_CR4","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1001\/jamaoncol.2018.0271","volume":"4","author":"R Mano","year":"2018","unstructured":"Mano R, Tamir S, Kedar I, Benjaminov O, Baniel J, Tabachnik T, Margel D. Malignant abnormalities in male BRCA mutation carriers: results from a prospectively screened cohort. JAMA Oncol. 2018;4(6):872\u20134.","journal-title":"JAMA Oncol"},{"key":"1957_CR5","unstructured":"Petrucelli N DM, Pal T. : BRCA1- and BRCA2- Associated Hereditary Breast and Ovarian Cancer. In: GeneReviews\u00ae edn. Edited by Adam MP FJ, Mirzaa GM, et al. Seattle (WA): University of Washington, Seattle; 2023."},{"key":"1957_CR6","doi-asserted-by":"publisher","first-page":"674094","DOI":"10.3389\/fgene.2021.674094","volume":"12","author":"Y Su","year":"2021","unstructured":"Su Y, Yao Q, Xu Y, Yu C, Zhang J, Wang Q, Li J, Shi D, Yu B, Zeng Y, et al. Characteristics of germline non-BRCA mutation status of high-risk breast cancer patients in china and correlation with high-risk factors and multigene testing suggestions. Front Genet. 2021;12:674094.","journal-title":"Front Genet"},{"issue":"4","key":"1957_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/j.ajhg.2009.08.018","volume":"85","author":"SV Tavtigian","year":"2009","unstructured":"Tavtigian SV, Oefner PJ, Babikyan D, Hartmann A, Healey S, Le Calvez-Kelm F, Lesueur F, Byrnes GB, Chuang SC, Forey N, et al. Rare, evolutionarily unlikely missense substitutions in ATM confer increased risk of breast cancer. Am J Hum Genet. 2009;85(4):427\u201346.","journal-title":"Am J Hum Genet"},{"issue":"6","key":"1957_CR8","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1086\/426403","volume":"75","author":"C Cybulski","year":"2004","unstructured":"Cybulski C, Gorski B, Huzarski T, Masojc B, Mierzejewski M, Debniak T, Teodorczyk U, Byrski T, Gronwald J, Matyjasik J, et al. CHEK2 is a multiorgan cancer susceptibility gene. Am J Hum Genet. 2004;75(6):1131\u20135.","journal-title":"Am J Hum Genet"},{"issue":"1","key":"1957_CR9","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/ng879","volume":"31","author":"H Meijers-Heijboer","year":"2002","unstructured":"Meijers-Heijboer H, van den Ouweland A, Klijn J, Wasielewski M, de Snoo A, Oldenburg R, Hollestelle A, Houben M, Crepin E, van Veghel-Plandsoen M, et al. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations. Nat Genet. 2002;31(1):55\u20139.","journal-title":"Nat Genet"},{"issue":"6","key":"1957_CR10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1056\/NEJMoa1400382","volume":"371","author":"AC Antoniou","year":"2014","unstructured":"Antoniou AC, Casadei S, Heikkinen T, Barrowdale D, Pylkas K, Roberts J, Lee A, Subramanian D, De Leeneer K, Fostira F, et al. Breast-cancer risk in families with mutations in PALB2. N Engl J Med. 2014;371(6):497\u2013506.","journal-title":"N Engl J Med"},{"issue":"6","key":"1957_CR11","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1158\/0008-5472.CAN-10-3958","volume":"71","author":"S Casadei","year":"2011","unstructured":"Casadei S, Norquist BM, Walsh T, Stray S, Mandell JB, Lee MK, Stamatoyannopoulos JA, King MC. Contribution of inherited mutations in the BRCA2-interacting protein PALB2 to familial breast cancer. Cancer Res. 2011;71(6):2222\u20139.","journal-title":"Cancer Res"},{"issue":"1","key":"1957_CR12","doi-asserted-by":"publisher","first-page":"a001008","DOI":"10.1101\/cshperspect.a001008","volume":"2","author":"M Olivier","year":"2010","unstructured":"Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"6","key":"1957_CR13","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/s41588-020-0609-2","volume":"52","author":"H Zhang","year":"2020","unstructured":"Zhang H, Ahearn TU, Lecarpentier J, Barnes D, Beesley J, Qi G, Jiang X, O\u2019Mara TA, Zhao N, Bolla MK, et al. Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nat Genet. 2020;52(6):572\u201381.","journal-title":"Nat Genet"},{"issue":"9","key":"1957_CR14","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/s41588-023-01466-z","volume":"55","author":"N Wilcox","year":"2023","unstructured":"Wilcox N, Dumont M, Gonzalez-Neira A, Carvalho S, Joly Beauparlant C, Crotti M, Luccarini C, Soucy P, Dubois S, Nunez-Torres R, et al. Exome sequencing identifies breast cancer susceptibility genes and defines the contribution of coding variants to breast cancer risk. Nat Genet. 2023;55(9):1435\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"1957_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13058-021-01484-x","volume":"24","author":"TU Ahearn","year":"2022","unstructured":"Ahearn TU, Zhang H, Michailidou K, Milne RL, Bolla MK, Dennis J, Dunning AM, Lush M, Wang Q, Andrulis IL, et al. Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Res. 2022;24(1):2.","journal-title":"Breast Cancer Res"},{"issue":"10","key":"1957_CR16","doi-asserted-by":"publisher","first-page":"2682","DOI":"10.1002\/ijc.32304","volume":"145","author":"L Feliubadalo","year":"2019","unstructured":"Feliubadalo L, Lopez-Fernandez A, Pineda M, Diez O, Del Valle J, Gutierrez-Enriquez S, Teule A, Gonzalez S, Stjepanovic N, Salinas M, et al. Opportunistic testing of BRCA1, BRCA2 and mismatch repair genes improves the yield of phenotype driven hereditary cancer gene panels. Int J Cancer. 2019;145(10):2682\u201391.","journal-title":"Int J Cancer"},{"key":"1957_CR17","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.breast.2019.01.002","volume":"45","author":"C Colas","year":"2019","unstructured":"Colas C, Golmard L, de Pauw A, Caputo SM, Stoppa-Lyonnet D. \u201cDecoding hereditary breast cancer\u201d benefits and questions from multigene panel testing. Breast. 2019;45:29\u201335.","journal-title":"Breast"},{"key":"1957_CR18","doi-asserted-by":"crossref","unstructured":"Urbina-Jara LK, Rojas-Martinez A, Martinez-Ledesma E, Aguilar D, Villarreal-Garza C, Ortiz-Lopez R: Landscape of germline mutations in DNA repair genes for breast cancer in latin america: opportunities for PARP-like inhibitors and immunotherapy. Genes (Basel) 2019, 10(10)","DOI":"10.3390\/genes10100786"},{"issue":"1","key":"1957_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.21149\/12704","volume":"64","author":"Y Chavarri-Guerra","year":"2022","unstructured":"Chavarri-Guerra Y, Villarreal-Garza C, Ferrigno AS, Mohar A, Aguilar D, Alvarez-Gomez RM, Gallardo-Alvarado L, Del Toro-Valero A, Quintero-Beulo G, Gutierrez-Delgado F, et al. Germline pathogenic variants in Mexican patients with hereditary triple-negative breast cancer. Salud Publica Mex. 2022;64(1):41\u20138.","journal-title":"Salud Publica Mex"},{"key":"1957_CR20","doi-asserted-by":"crossref","unstructured":"Perez-Ibave DC, Garza-Rodriguez ML, Noriega-Iriondo MF, Flores-Moreno SM, Gonzalez-Geroniz MI, Espinoza-Velazco A, Castruita-Avila AL, Alcorta-Nunez F, Zayas-Villanueva OA, Gonzalez-Guerrero JF et al: Identification of germline variants in patients with hereditary cancer syndromes in northeast Mexico. Genes (Basel) 2023, 14(2).","DOI":"10.3390\/genes14020341"},{"issue":"1","key":"1957_CR21","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-018-4726-x","volume":"170","author":"J Singh","year":"2018","unstructured":"Singh J, Thota N, Singh S, Padhi S, Mohan P, Deshwal S, Sur S, Ghosh M, Agarwal A, Sarin R, et al. Screening of over 1000 Indian patients with breast and\/or ovarian cancer with a multi-gene panel: prevalence of BRCA1\/2 and non-BRCA mutations. Breast Cancer Res Treat. 2018;170(1):189\u201396.","journal-title":"Breast Cancer Res Treat"},{"key":"1957_CR22","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Genetic\/Familial, High-Risk Assessment: Breast, Ovarian, and Pancreatic [https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_bop.pdf, ]"},{"key":"1957_CR23","unstructured":"NCCN Guidelines: Genetic\/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic [https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=2&id=1503]"},{"key":"1957_CR24","doi-asserted-by":"publisher","first-page":"789659","DOI":"10.3389\/fonc.2021.789659","volume":"11","author":"VT Tran","year":"2021","unstructured":"Tran VT, Nguyen ST, Pham XD, Phan TH, Nguyen VC, Nguyen HT, Nguyen HP, Doan PTT, Le TA, Nguyen BT, et al. Pathogenic variant profile of hereditary cancer syndromes in a vietnamese cohort. Front Oncol. 2021;11:789659.","journal-title":"Front Oncol"},{"issue":"8","key":"1957_CR25","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1136\/jmedgenet-2018-105700","volume":"56","author":"A Stradella","year":"2019","unstructured":"Stradella A, Del Valle J, Rofes P, Feliubadalo L, Grau Garces E, Velasco A, Gonzalez S, Vargas G, Izquierdo A, Campos O, et al. Does multilocus inherited neoplasia alleles syndrome have severe clinical expression? J Med Genet. 2019;56(8):521\u20135.","journal-title":"J Med Genet"},{"issue":"2","key":"1957_CR26","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M. Targeting DNA damage response pathways in cancer. Nat Rev Cancer. 2023;23(2):78\u201394.","journal-title":"Nat Rev Cancer"},{"issue":"20","key":"1957_CR27","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/ijms21207504","volume":"21","author":"C Nastasi","year":"2020","unstructured":"Nastasi C, Mannarino L, D\u2019Incalci M. DNA damage response and immune defense. Int J Mol Sci. 2020;21(20):96.","journal-title":"Int J Mol Sci"},{"key":"1957_CR28","doi-asserted-by":"publisher","first-page":"797880","DOI":"10.3389\/fimmu.2021.797880","volume":"12","author":"Z Ye","year":"2021","unstructured":"Ye Z, Shi Y, Lees-Miller SP, Tainer JA. Function and molecular mechanism of the DNA damage response in immunity and cancer immunotherapy. Front Immunol. 2021;12:797880.","journal-title":"Front Immunol"},{"key":"1957_CR29","unstructured":"Quezada Urban R, Diaz Velasquez CE, Gitler R, Rojo Castillo MP, Sirota Toporek M, Figueroa Morales A, Moreno Garcia O, Garcia Esquivel L, Torres Mejia G, Dean M et al: Comprehensive analysis of germline variants in mexican patients with hereditary breast and ovarian cancer susceptibility. Cancers (Basel) 2018, 10(10)."},{"key":"1957_CR30","doi-asserted-by":"crossref","unstructured":"Chavarri-Guerra YVG, C.; Rodriguez-Olivares, J.L.; Aguilar-y Mendez, D.; Quintero-Beulo, G.; Gutierrez-Delgado, F., Herzog, J.; Gruber, S.: Abstract P6\u201302\u201305. Prevalence of non-BRCA germline pathogenic variants in Mexican women with breast cancer referred for genetic cancer risk assessment. In: POSTER SESSION ABSTRACTS| MARCH 01 2023. vol. Cancer Res (2023) 83 (5_Supplement): P6\u201302\u201305.: American Association for Cancer Research; 2023.","DOI":"10.1158\/1538-7445.SABCS22-P6-02-05"},{"key":"1957_CR31","unstructured":"National Comprehensive Cancer Network (NCCN). Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae). Genetic\/Familial High-Risk Assessment: Colorectal. [https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/genetics_colon.pdf ]"},{"issue":"1","key":"1957_CR32","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.jmoldx.2016.10.002","volume":"19","author":"MM Li","year":"2017","unstructured":"Li MM, Datto M, Duncavage EJ, Kulkarni S, Lindeman NI, Roy S, Tsimberidou AM, Vnencak-Jones CL, Wolff DJ, Younes A, et al. Standards and guidelines for the interpretation and reporting of sequence variants in cancer: a joint consensus recommendation of the association for molecular pathology, american society of clinical oncology, and college of american pathologists. J Mol Diagn. 2017;19(1):4\u201323.","journal-title":"J Mol Diagn"},{"issue":"D1","key":"1957_CR33","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum MJ, Lee JM, Benson M, Brown GR, Chao C, Chitipiralla S, Gu B, Hart J, Hoffman D, Jang W, et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 2018;46(D1):D1062\u20137.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"1957_CR34","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.1093\/bioinformatics\/bty897","volume":"35","author":"C Kopanos","year":"2019","unstructured":"Kopanos C, Tsiolkas V, Kouris A, Chapple CE, Albarca Aguilera M, Meyer R, Massouras A. VarSome: the human genomic variant search engine. Bioinformatics. 2019;35(11):1978\u201380.","journal-title":"Bioinformatics"},{"issue":"4","key":"1957_CR35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1038\/s41416-021-01410-0","volume":"125","author":"D Wokolorczyk","year":"2021","unstructured":"Wokolorczyk D, Kluzniak W, Stempa K, Rusak B, Huzarski T, Gronwald J, Gliniewicz K, Kashyap A, Morawska S, Debniak T, et al. PALB2 mutations and prostate cancer risk and survival. Br J Cancer. 2021;125(4):569\u201375.","journal-title":"Br J Cancer"},{"key":"1957_CR36","doi-asserted-by":"crossref","unstructured":"Danishevich A, Bilyalov A, Nikolaev S, Khalikov N, Isaeva D, Levina Y, Makarova M, Nemtsova M, Chernevskiy D, Sagaydak O et al: CDKN2A gene mutations: implications for hereditary cancer syndromes. Biomedicines 2023, 11(12).","DOI":"10.3390\/biomedicines11123343"},{"issue":"1","key":"1957_CR37","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1007\/s10549-023-07173-x","volume":"204","author":"A Keske","year":"2024","unstructured":"Keske A, Weisman P, Ospina-Romero M, Raut P, Smith-Simmer K, Zakas AL, Flynn C, Xu J. Breast cancers in monoallelic MUTYH germline mutation carriers have clinicopathological features overlapping with those in BRCA1 germline mutation carriers. Breast Cancer Res Treat. 2024;204(1):151\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"1957_CR38","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1016\/j.pathol.2017.03.002","volume":"49","author":"MG Keeney","year":"2017","unstructured":"Keeney MG, Couch FJ, Visscher DW, Lindor NM. Non-BRCA familial breast cancer: review of reported pathology and molecular findings. Pathology. 2017;49(4):363\u201370.","journal-title":"Pathology"},{"issue":"35","key":"1957_CR39","doi-asserted-by":"publisher","first-page":"4409","DOI":"10.1200\/JCO.2012.43.2278","volume":"30","author":"C Engel","year":"2012","unstructured":"Engel C, Loeffler M, Steinke V, Rahner N, Holinski-Feder E, Dietmaier W, Schackert HK, Goergens H, von Knebel DM, Goecke TO, et al. Risks of less common cancers in proven mutation carriers with lynch syndrome. J Clin Oncol. 2012;30(35):4409\u201315.","journal-title":"J Clin Oncol"},{"issue":"7","key":"1957_CR40","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.gastrohep.2015.11.009","volume":"39","author":"ML Leoz","year":"2016","unstructured":"Leoz ML, Sanchez A, Carballal S, Ruano L, Ocana T, Pellise M, Castells A, Balaguer F, Moreira L. Hereditary gastric and pancreatic cancer predisposition syndromes. Gastroenterol Hepatol. 2016;39(7):481\u201393.","journal-title":"Gastroenterol Hepatol"},{"issue":"2","key":"1957_CR41","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.ygyno.2022.05.023","volume":"166","author":"B Heald","year":"2022","unstructured":"Heald B, Mokhtary S, Nielsen SM, Rojahn S, Yang S, Michalski ST, Esplin ED. Unexpected actionable genetic variants revealed by multigene panel testing of patients with uterine cancer. Gynecol Oncol. 2022;166(2):344\u201350.","journal-title":"Gynecol Oncol"},{"key":"1957_CR42","doi-asserted-by":"crossref","unstructured":"Liu TF, Y.; Feng, R; Zhou, L.; Gu, Y.; Dong, D.;Yi, H.; Yang, X.; Wang, C.: Wide morphological spectrums of renal neoplasms with TSC\/mTOR, NF2, or monoallelic MUTYH germline mutation. Hum Pathol Rep 2023, 31: 96.","DOI":"10.1016\/j.hpr.2023.300695"},{"key":"1957_CR43","doi-asserted-by":"publisher","first-page":"104058","DOI":"10.1016\/j.critrevonc.2023.104058","volume":"188","author":"JM Hernandez-Martinez","year":"2023","unstructured":"Hernandez-Martinez JM, Rosell R, Arrieta O. Somatic and germline ATM variants in non-small-cell lung cancer: therapeutic implications. Crit Rev Oncol Hematol. 2023;188:104058.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1957_CR44","doi-asserted-by":"crossref","unstructured":"Maffuz-Aziz AL-A, S.; Espejo-Fonsecac, A.; Rodriguez-Cuevasa, S.: Clinical and pathological features of breast cancer in a population of Mexico. Cirug\u00eda y Cirujanos 2017, May.","DOI":"10.1016\/j.circen.2017.05.010"},{"issue":"3","key":"1957_CR45","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1007\/s10549-012-1993-9","volume":"133","author":"S Masciari","year":"2012","unstructured":"Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, Gruber SB, Ford JM, Euhus D, Lebensohn A, et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat. 2012;133(3):1125\u201330.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"1957_CR46","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s10549-023-07176-8","volume":"204","author":"CJ Schwartz","year":"2024","unstructured":"Schwartz CJ, Khorsandi N, Blanco A, Mukhtar RA, Chen YY, Krings G. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants. Breast Cancer Res Treat. 2024;204(1):171\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"1957_CR47","doi-asserted-by":"publisher","first-page":"909","DOI":"10.3389\/fphar.2018.00909","volume":"9","author":"H Chen","year":"2018","unstructured":"Chen H, Wu J, Zhang Z, Tang Y, Li X, Liu S, Cao S, Li X. Association between BRCA status and triple-negative breast cancer: a meta-analysis. Front Pharmacol. 2018;9:909.","journal-title":"Front Pharmacol"},{"issue":"2","key":"1957_CR48","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1007\/s10549-020-05543-3","volume":"180","author":"I Rainville","year":"2020","unstructured":"Rainville I, Hatcher S, Rosenthal E, Larson K, Bernhisel R, Meek S, Gorringe H, Mundt E, Manley S. High risk of breast cancer in women with biallelic pathogenic variants in CHEK2. Breast Cancer Res Treat. 2020;180(2):503\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"1957_CR49","doi-asserted-by":"publisher","first-page":"101101","DOI":"10.1016\/j.gim.2024.101101","volume":"26","author":"S Hinic","year":"2024","unstructured":"Hinic S, Cybulski C, Van der Post RS, Vos JR, Schuurs-Hoeijmakers J, Brugnoletti F, Koene S, Vreede L, van Zelst-Stams WAG, Kets CM, et al. The heterogeneous cancer phenotype of individuals with biallelic germline pathogenic variants in CHEK2. Genet Med. 2024;26(5):101101.","journal-title":"Genet Med"},{"key":"1957_CR50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/JGO.19.11000","volume":"5","author":"C Adaniel","year":"2019","unstructured":"Adaniel C, Salinas F, Donaire JM, Bravo ME, Peralta O, Paredes H, Aliaga N, Sola A, Neira P, Behnke C, et al. Non-BRCA1\/2 variants detected in a high-risk chilean cohort with a history of breast and\/or ovarian cancer. J Glob Oncol. 2019;5:1\u201314.","journal-title":"J Glob Oncol"},{"issue":"6","key":"1957_CR51","doi-asserted-by":"publisher","first-page":"101008","DOI":"10.1016\/j.currproblcancer.2023.101008","volume":"47","author":"L Fernandez Madrigal","year":"2023","unstructured":"Fernandez Madrigal L, Rodriguez Garces MY, Jimenez Ruiz FJ. Impact of non-BRCA genes in the indication of risk-reducing surgery in hereditary breast and ovarian cancer syndrome (HBOC). Curr Probl Cancer. 2023;47(6):101008.","journal-title":"Curr Probl Cancer"},{"key":"1957_CR52","doi-asserted-by":"publisher","unstructured":"Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina. https:\/\/doi.org\/10.1200\/JCO.2023.41.16_suppl.e22534","DOI":"10.1200\/JCO.2023.41.16_suppl.e22534"},{"issue":"3","key":"1957_CR53","first-page":"220","volume":"92","author":"A Catana","year":"2019","unstructured":"Catana A, Apostu AP, Antemie RG. Multi gene panel testing for hereditary breast cancer - is it ready to be used? Med Pharm Rep. 2019;92(3):220\u20135.","journal-title":"Med Pharm Rep"},{"issue":"16","key":"1957_CR54","doi-asserted-by":"publisher","first-page":"2829","DOI":"10.1002\/cncr.32083","volume":"125","author":"JN Weitzel","year":"2019","unstructured":"Weitzel JN, Neuhausen SL, Adamson A, Tao S, Ricker C, Maoz A, Rosenblatt M, Nehoray B, Sand S, Steele L, et al. Pathogenic and likely pathogenic variants in PALB2, CHEK2, and other known breast cancer susceptibility genes among 1054 BRCA-negative Hispanics with breast cancer. Cancer. 2019;125(16):2829\u201336.","journal-title":"Cancer"},{"issue":"4","key":"1957_CR55","doi-asserted-by":"publisher","first-page":"3140","DOI":"10.18632\/aging.102783","volume":"12","author":"B Chen","year":"2020","unstructured":"Chen B, Zhang G, Li X, Ren C, Wang Y, Li K, Mok H, Cao L, Wen L, Jia M, et al. Comparison of BRCA versus non-BRCA germline mutations and associated somatic mutation profiles in patients with unselected breast cancer. Aging (Albany NY). 2020;12(4):3140\u201355.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"1957_CR56","doi-asserted-by":"publisher","first-page":"17769","DOI":"10.1038\/s41598-019-54170-6","volume":"9","author":"J Dutil","year":"2019","unstructured":"Dutil J, Teer JK, Golubeva V, Yoder S, Tong WL, Arroyo N, Karam R, Echenique M, Matta JL, Monteiro AN. Germline variants in cancer genes in high-risk non-BRCA patients from Puerto Rico. Sci Rep. 2019;9(1):17769.","journal-title":"Sci Rep"},{"issue":"1","key":"1957_CR57","doi-asserted-by":"publisher","first-page":"4190","DOI":"10.1038\/s41598-022-07383-1","volume":"12","author":"RSC Guindalini","year":"2022","unstructured":"Guindalini RSC, Viana DV, Kitajima J, Rocha VM, Lopez RVM, Zheng Y, Freitas E, Monteiro FPM, Valim A, Schlesinger D, et al. Detection of germline variants in Brazilian breast cancer patients using multigene panel testing. Sci Rep. 2022;12(1):4190.","journal-title":"Sci Rep"},{"issue":"1","key":"1957_CR58","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-022-06855-2","volume":"198","author":"QT Tan","year":"2023","unstructured":"Tan QT, Alcantara VS, Sultana R, Loh KW, Go AL, Wong FY. Pregnancy-associated breast cancer: a multicenter study comparing clinicopathological factors, diagnosis and treatment outcomes with non-pregnant patients. Breast Cancer Res Treat. 2023;198(1):53\u201366.","journal-title":"Breast Cancer Res Treat"},{"issue":"9193","key":"1957_CR59","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1016\/S0140-6736(99)04336-6","volume":"354","author":"H Jernstrom","year":"1999","unstructured":"Jernstrom H, Lerman C, Ghadirian P, Lynch HT, Weber B, Garber J, Daly M, Olopade OI, Foulkes WD, Warner E, et al. Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2. Lancet. 1999;354(9193):1846\u201350.","journal-title":"Lancet"},{"issue":"6","key":"1957_CR60","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1002\/ijc.21273","volume":"117","author":"CA Cullinane","year":"2005","unstructured":"Cullinane CA, Lubinski J, Neuhausen SL, Ghadirian P, Lynch HT, Isaacs C, Weber B, Moller P, Offit K, Kim-Sing C, et al. Effect of pregnancy as a risk factor for breast cancer in BRCA1\/BRCA2 mutation carriers. Int J Cancer. 2005;117(6):988\u201391.","journal-title":"Int J Cancer"}],"container-title":["Breast Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01957-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13058-024-01957-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13058-024-01957-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,15]],"date-time":"2025-01-15T11:26:56Z","timestamp":1736940416000},"score":1,"resource":{"primary":{"URL":"https:\/\/breast-cancer-research.biomedcentral.com\/articles\/10.1186\/s13058-024-01957-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,15]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1957"],"URL":"https:\/\/doi.org\/10.1186\/s13058-024-01957-9","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4144612\/v1","asserted-by":"object"}]},"ISSN":["1465-542X"],"issn-type":[{"value":"1465-542X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,15]]},"assertion":[{"value":"21 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted according to the guidelines of the Declaration of Helsinki and approved by the Institutional Review Board of the Hospital Universitario\u201d Dr. Jos\u00e9 Eleuterio Gonz\u00e1lez\u201d from the Universidad Aut\u00f3noma de Nuevo Le\u00f3n (protocol code ON18- 00015).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All patients voluntarily consented to participate in this study by signing an informed consent, approved by the ethics committee of our institution.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"7"}}